Our present study introduces new findings, explores different cell lines, new drugs, and analyzes new cell processes (autophagy and cell cycle) and new molecules of the signaling pathway with Western blotting and in situ immunofluorescence, giving strength to the concept that dual targeting of Gli1 and Akt represents a mechanistically and potentially translatable therapeutic approach in this aggressive leukemia subtype [49]. The gene discussed is AKT1; the disease is leukemia.